Print Friendly, PDF & Email

NCT/Study#

NCT04196491 /

BB-2121-MM-004

A Phase 1, Open-Label, Multicenter Study To Evaluate The Safety Of Bb2121 In Subjects With High Risk, Actively Diagnosed Multiple Myeloma (Karmma-4)

DISEASE GROUP:

Multiple Myeloma

current phase:

Phase I

STUDY STATUS:

Accepting Patients

Location:

Hackensack, NJ

For More information:

Call 201-518-3587